Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
611 in moderate to severe COPD
NCT06099652Phase 2Completed
- Sponsor
- 3S Guojian Pharmaceutical
- Start
- Dec 2023
- Primary completion
- Apr 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of SSGJ-611 in chronic obstructive pulmonary disease (COPD), sponsored by 3S Guojian Pharmaceutical. Started Dec 2023; status: completed.
02
Drugs
SSGJ-611
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT06099652.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06099652.